Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry

University Hospital Basel

Status: Not yet enrolling

Conditions: Cradiovascular-kidney-liver-metabolic (CKLM) Syndrome; Cardiovascular-kidney-metabolic Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT07084688

2025-00756 am25Vischer;

Details and patient eligibility

About

The aim of this clinical and exploratory Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry is to establish high quality prevalence and incidence database for Cardiovascular-Kidney-Metabolic (CKM) syndrome, its major contributors, and the extent of the respective organ damaged.

Full description

The Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry is a prospective, longitudinal, non-interventional registry based at the Medical Outpatient Department of the University Hospital Basel. It aims to address key knowledge gaps related to (I) the prevalence, incidence, and heterogeneity of CKLM syndrome and its clinical phenotypes, (II) liver involvement, (III) emerging therapies, and (IV) the need for interdisciplinary care and integrated management. The registry supports improved understanding and management of this complex syndrome in routine clinical practice.

Enrollment: 1,500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• At least 18 years of age

• Individuals diagnosed with cardiovascular-kidney-metabolic (CKM) syndrome stages 0 to 3 according to the American Heart Association (AHA) or liver disease defined by any of the following:

  • For stage 0: Individuals without overweight/obesity, metabolic risk factors (normoglycemia, normotension, normal lipid profile), Chronic kidney disease (CKD), or Cardiovascular disease (CVD)
  • Individuals with overweight/obesity or dysfunctional adipose tissue, without other metabolic risk factors or CKD
  • Individuals with metabolic risk factors (hypertriglyceridemia, arterial hypertension, metabolic syndrome, diabetes) or CKD
  • Subclinical Atherosclerotic cardiovascular disease (ASCVD) or subclinical heart failure (HF) in individuals with excess/dysfunctional adiposity, other metabolic risk factors, or CKD in the clinical assessment[2]
  • Independent of CKM syndrome stages, individual with signs of hepatic steatosis on imaging

• Willingness to provide informed consent

Exclusion criteria

• Individuals with CKM syndrome stage 4 according to the AHA

  * Individuals with clinical cardiovascular disease including:

  • History of coronary artery disease, myocardial infarction, coronary artery intervention
  • History of atrial fibrillation
  • History of stroke
  • Symptomatic peripheral artery disease (>stage I)
  • History of symptomatic HF
  • History of HF hospitalisation

• Inability to sign informed consent